Abstract: Objective To evaluate the frequency, distribution and clinical significance of the antibodies to the fetal and/or adult acetylcholine receptor (AChR) in patients with myasthenia gravis (MG). Methods AChR antibodies were detected by cell-based assay in the serum of ocular MG (OMG) (n = 90) and generalized MG (GMG) patients (n = 110). The fetaltype (2α: β: γ: δ) and adult-type (2α: β: ε: δ) AChR were used as antigens, and their relevance to disease presentation was assessed. Results The overall frequencies of anti-adult and anti-fetal AChR antibodies were similar in all 200 patients examined, with 14 having serum specific to the AChR-γ subunit, and 22 to the AChR-ε subunit. The overall sensitivity when using the fetal and adult AChR antibodies was higher than that when using the fetal AChR antibody only (P = 0.015).
Introduction
Myasthenia gravis (MG) is an autoimmune disease mediated by antibodies to the muscle acetylcholine receptor (AChR) and other muscle antigens, which cause a neuromuscular transmission disorder [1, 2] . Ptosis or double vision occurs as the initial symptom of MG in more than 75% of patients, and in nearly all patients at some time in the course of generalized MG (GMG) [3] . Up to 80% of patients who present with ocular manifestations develop generalized muscle weakness within 2 years [4] [5] [6] . However, in some patients, the symptoms are restricted to the ocular muscles for more than 2 years, and this is defined as ocular [7, 8] . A previous study showed that the presence of anti-AChR antibody is associated with an increased risk of secondary generalization of muscular weakness [9] . However, which type of anti-AChR antibody is involved in the transition from MG with initial ocular symptom to GMG needs to be clarified.
Human muscle AChR has two subtypes, fetal and adult; anti-AChR antibodies are thus heterogeneous. Fetal
AChR is composed of four subunits in a pentameric structure with 2α: β: γ: δ stoichiometry, and in the adult subtype (2α: β: ε: δ), the γ subunit is replaced by the ε subunit [10, 11] .
Many MG patients have a negative, equivocal, or low titer when detecting AChR antibodies using AChR from denervated human muscle that expresses mainly the fetal isoform [12] . In this study, we used a cell-based assay (CBA) [8, 14] . According to the symptoms at disease onset, patients in Group II were further divided into two subgroups. Group IIa: generalized weakness at disease onset, either subjectively or revealed during neurological examination; Group IIb: only ocular muscle involvement during the first months, but transformation to GMG later.
Materials cDNAs encoding the human AChR sub-
units α, β, δ, ε and γ were cloned into pcDNA3.1/Hygro vector. Human rapsyn cDNA was cloned into pEGFP-N1.
pEGFP-N1 was used as a control plasmid [14] . All the plasmids used in this study were kind gifts from Professor
Angela Vincent and Professor David Beeson, Nuffield
Department of Clinical Neurosciences, University of Oxford.
CBA for AChR antibodies Detection of antibodies
to the fetal-type and adult-type AChRs were conducted by CBA based on previous reports [2, 15] . Human embryonic kidney 293 cells were seeded and allowed to grow for at least 24 h in 24-well plates. When the cells were 40%-50% confluent, they were transfected with fetal or adult AChR subunits, and EGFP-tagged rapsyn was used for during the second year, and 3.6% (2/55) had generalized weakness after the first 2 years.
Statistical analysis

Determination of fetal and adult AChR antibodies
Antibodies to adult or fetal AChR were all negative in the healthy subjects and disease controls. Among the 60 adult AChR-Ab, acetylcholine receptor antibody.
ratio of antibodies was 77% (154/200) when both fetal and adult AChR were used as the antigens. The overall sensitivity when using adult and fetal types combined was increased by 11% compared with the result using fetal AChR antigen only (P = 0.015). There was a trend toward higher sensitivity in the adult and fetal AChR antigen group than in the adult AChR antigen group, but this difference did not reach significance (P = 0.113).
Distribution of AChR antibodies in MG patients
with different clinical types The positive ratio of antifetal and/or anti-adult antibodies was 71% (64/90) in group I, 73% (40/55) in group IIa, and 91% (50/55) in group IIb.
There was a significant difference between groups I and IIb (P = 0.005). The frequency of antibodies to both adult and fetal AChR was higher in group IIb (82%) than in group I (42%) (P <0.001) ( 
Discussion
In this study, we found that 37 of the 55 MG patients who initially presented only with ocular muscle weakness developed GMG within 1 year. These results are consistent with previous reports that most MG patients with initial ocular symptom progress to GMG within 1 year [5, 17] . The risk for developing GMG decreased when the duration of OMG exceeded 1 year and was even lower after 2 years.
To some extent, our results confirmed and also extended the previous reports. Thus, it might be more efficacious to prevent GMG during the first year.
Anti-AChR antibodies are heterogeneous. The α subunit is thought to be immunodominant, bearing the main immunogenic regions [18, 19] , and breakdown of tolerance to a self-peptide of the AChR α-subunit can induce experimental MG in rats [20] . Further support for this notion is the observation that the majority of MG serum samples bind to determinants on the α-subunit [21, 22] . However, the immunogenicity of the non-α subunits has been less well studied.
Since anti-AChR subunit-specific antibodies are present in MG sera [15, 23] , it is therefore necessary to assess the antibodies in MG patients with combined fetal and adult
AChRs. Our present results not only confirmed previous reports, but also revealed the distribution of autoantibodies to the AChR ε or γ subunit in MG patients with different clinical types. In contrast to a previous report that the levator palpebrae muscles do not contain detectable AChR γ [24] , some of our patients whose sera reacted only with fetal AChR did present with ptosis. It is possible that in cases with such low levels of anti-AChR antibody, some of the relevant specific antibodies had been adsorbed by the muscle end plates, so the detectable circulating antibodies were not entirely representative of those that are pathogenic. In addition, a study reported that anti-fetal AChR-specific antibodies alone are insufficient to cause ocular muscle weakness [10] . However, we found that two patients with GMG had antibodies that bound only to the AChR γ subunit. It appears that anti-fetal AChR-specific antibodies alone may be sufficient to cause generalized muscle weakness.
Conventional diagnostic radioimmunoassays use fetal
AChR as the antigen [12] . Presumably, this method fails to detect antibodies that only bind to the anti-AChR ε subunit. Our results demonstrated that anti-AChR ε and antiAChR γ subunit-specific antibodies coexist in MG patients.
Compared with the fetal-type AChR antigen group, the positive ratio of AChR antibodies increased when both isoforms were used as the antigens in MG patients. Although there was no significant statistical difference, the positive ratio of AChR antibodies in the fetal and adult AChR antigen group tended to be higher than in the group with adult AChR antigen alone. This suggests that this assay, which uses both fetal and adult type AChR as the antigens, may be more sensitive than the assay that uses only fetal or adult type AChR as the antigen in MG patients.
It is known that, except for the levator palpebrae muscles, extraocular muscles express both adult and fetal isoforms of the AChR [25] . Therefore there are two kinds of anti-AChR antibodies in the serum of OMG patients, but the frequency of antibodies to both isoforms and its predictive value for OMG converting to GMG has not been well studied. We found that the positive ratios of overall AChR antibodies and those that bound to both isoforms were significantly higher in GMG patients who converted than in the OMG patients. The risk for developing GMG increased in patients with antibodies for both fetal and adult AChR, although a previous study showed that the risk of GMG was only slightly increased in patients with abnormal AChR antibody levels [4] . In addition, we found that the mean age at disease onset for group IIb was significantly higher than for group I. The risk of developing GMG increased in older patients. This suggests that senior MG patients undergo conversion to GMG at a higher frequency.
